{
  "ProtocolSection": {
    "IdentificationModule": {
      "NCTId": "NCT02344849",
      "OrgStudyIdInfo": {
        "OrgStudyId": "Cellgram-ED"
      },
      "Organization": {
        "OrgFullName": "Pharmicell Co., Ltd.",
        "OrgClass": "INDUSTRY"
      },
      "BriefTitle": "Safety of Autologous Bone Marrow Derived Mesenchymal Stem Cells in Erectile Dysfunction",
      "OfficialTitle": "An Open, Single-center, Phase 1 Study to Evaluate Safety of Autologous Bone Marrow Derived Mesenchymal Stem Cell in Erectile Dysfunction."
    },
    "StatusModule": {
      "StatusVerifiedDate": "January 2019",
      "OverallStatus": "Completed",
      "ExpandedAccessInfo": {
        "HasExpandedAccess": "No"
      },
      "StartDateStruct": {
        "StartDate": "July 2015"
      },
      "PrimaryCompletionDateStruct": {
        "PrimaryCompletionDate": "January 31, 2018",
        "PrimaryCompletionDateType": "Actual"
      },
      "CompletionDateStruct": {
        "CompletionDate": "April 2018",
        "CompletionDateType": "Actual"
      },
      "StudyFirstSubmitDate": "January 13, 2015",
      "StudyFirstSubmitQCDate": "January 18, 2015",
      "StudyFirstPostDateStruct": {
        "StudyFirstPostDate": "January 26, 2015",
        "StudyFirstPostDateType": "Estimate"
      },
      "LastUpdateSubmitDate": "January 7, 2019",
      "LastUpdatePostDateStruct": {
        "LastUpdatePostDate": "January 9, 2019",
        "LastUpdatePostDateType": "Actual"
      }
    },
    "SponsorCollaboratorsModule": {
      "ResponsibleParty": {
        "ResponsiblePartyType": "Sponsor"
      },
      "LeadSponsor": {
        "LeadSponsorName": "Pharmicell Co., Ltd.",
        "LeadSponsorClass": "INDUSTRY"
      }
    },
    "OversightModule": {
      "OversightHasDMC": "No"
    },
    "DescriptionModule": {
      "BriefSummary": "This phase I clinical trial is designed to evaluate the safety of autologous Mesenchymal Stem Cells (MSC) injected intracavernously.",
      "DetailedDescription": "Cellgram-ED is autologous bone marrow-derived mesenchymal stem cells ex vivo expanded for approximately 30 days. Ten patients (Diabetes -associated ED; 5 patients, Postprostatectomy; 5patients) will be injected Cellgram-ED directly into the intracavernous. Patient will be evaluated the safety and potential efficacy of MSC."
    },
    "ConditionsModule": {
      "ConditionList": {
        "Condition": [
          "Erectile Dysfunction"
        ]
      }
    },
    "DesignModule": {
      "StudyType": "Interventional",
      "PhaseList": {
        "Phase": [
          "Phase 1"
        ]
      },
      "DesignInfo": {
        "DesignAllocation": "N/A",
        "DesignInterventionModel": "Single Group Assignment",
        "DesignPrimaryPurpose": "Treatment",
        "DesignMaskingInfo": {
          "DesignMasking": "None (Open Label)"
        }
      },
      "EnrollmentInfo": {
        "EnrollmentCount": "10",
        "EnrollmentType": "Actual"
      }
    },
    "ArmsInterventionsModule": {
      "ArmGroupList": {
        "ArmGroup": [
          {
            "ArmGroupLabel": "Mesenchymal stem cell",
            "ArmGroupType": "Experimental",
            "ArmGroupDescription": "Patients will receive single intracavernous injection of Mesenchymal stem cell. Oral PDE5-inhibitor can take on demand.",
            "ArmGroupInterventionList": {
              "ArmGroupInterventionName": [
                "Drug: mesenchymal stem cell"
              ]
            }
          }
        ]
      },
      "InterventionList": {
        "Intervention": [
          {
            "InterventionType": "Drug",
            "InterventionName": "mesenchymal stem cell",
            "InterventionDescription": "Patients will receive single injection of Cellgram-ED( 30,000,000 mesenchymal stem cell) intracavernously.",
            "InterventionArmGroupLabelList": {
              "InterventionArmGroupLabel": [
                "Mesenchymal stem cell"
              ]
            },
            "InterventionOtherNameList": {
              "InterventionOtherName": [
                "Cellgram-ED"
              ]
            }
          }
        ]
      }
    },
    "OutcomesModule": {
      "PrimaryOutcomeList": {
        "PrimaryOutcome": [
          {
            "PrimaryOutcomeMeasure": "Number and severity of adverse events",
            "PrimaryOutcomeDescription": "Analyze the laboratory, vital sign, physical exam results from baseline to end of the study for investigate adverse reactions and view safety.\n\nAn SAE suggests a significant hazard, contraindication, side-effect, or precaution. With respect to human clinical experience, this includes any event that:\n\nResults in death. Is life-threatening.* Requires in-patient hospitalization or prolongation of existing hospitalization.\n\nResults in persistent or significant disability/incapacity. Is a congenital anomaly/birth defect. Other medically important condition\n\nLife-threatening in the definition of a SAE or adverse reaction refers to an event in which the patient was at risk of death at the time of event; it does not refer to an event, which hypothetically might have caused death if it were more severe.",
            "PrimaryOutcomeTimeFrame": "12month"
          }
        ]
      },
      "SecondaryOutcomeList": {
        "SecondaryOutcome": [
          {
            "SecondaryOutcomeMeasure": "Change From Baseline in the International Index of Erectile Function(IIEF)",
            "SecondaryOutcomeDescription": "Description of the average variation from the screening value in each group using the Student's preordered t-test (Wilcoxon's signed bank test).\n\nFunction domain\n\nErectile Function (Q1,2,3,4,5,15) : Min 6 ~ Max 30\nOrgasmic Function (Q9,10) : Min 2 ~ Max 10\nSexual Desire (Q11,12) : : Min 2 ~ Max 10\nIntercourse Satisfaction (Q6,7,8): : Min 3 ~ Max 15\nOverall Satisfaction (Q13,14) : Min 2 ~ Max 10",
            "SecondaryOutcomeTimeFrame": "month 1, 3, 6, 9 and 12"
          },
          {
            "SecondaryOutcomeMeasure": "Penile Doppler Sonography, PDS",
            "SecondaryOutcomeDescription": "Change From Baseline in Peak systolic velocity (PSV) and End diastolic velocity (EDV), Evaluate Erection rigidity During the test.\n\nThe normal maximum systolic blood flow of the cavernosal artery after injection of vasodilators is 30 cm / s or more.\n\nPDS results are obtained 5 min, 10 min, 15 min, 20 min, 25 min and 30 min after intracavernosal injection.\n\nThe peak systolic velocity (PSV) is assessed as follows:\n\n>25 cm/s is considered to be normal, 20-25 cm/s is considered to be mild ED, 12-20 cm/s is considered to be moderate ED, <12 cm/s is considered to be severe arteriogenic impotence.\n\nThe end diastolic velocity (EDV) is assessed as follows:\n\n5 cm/s is considered to be a normal value, >5 cm/s is considered to indicate a veno-occlusive disorder.",
            "SecondaryOutcomeTimeFrame": "month 6, 12"
          },
          {
            "SecondaryOutcomeMeasure": "Change From Baseline in Sexual Encounter Profile (SEP) Question 2",
            "SecondaryOutcomeDescription": "The SEP2 survey describes cumulative success rates for 30 days, 3 months, 6 months, 9 months and 12 months after cell treatment.\n\nSEP 2 Were you able to insert your penis into your partner's vagina? Yes or No SEP 3 Did your erection last long enough to have successful intercourse? Yes or No",
            "SecondaryOutcomeTimeFrame": "month 1, 3, 6, 9 and 12"
          },
          {
            "SecondaryOutcomeMeasure": "Global Assessment Question (GAQ)",
            "SecondaryOutcomeDescription": "The GAQ survey describes cumulative success rates for 30 days, 3 months, 6 months, 9 months and 12 months after cell treatment.\n\nGAQ\n\nDid Cellgram-ED improve your Erectile Function? Yes or No\nIf so, did Cellgram-ED improve the ability to have sex? Yes or No",
            "SecondaryOutcomeTimeFrame": "month 1, 3, 6, 9 and 12"
          }
        ]
      }
    },
    "EligibilityModule": {
      "EligibilityCriteria": "Inclusion Criteria:\n\nPostprostatectomy Erectile Dysfunction\n\nA man aged 20 or older\nWho is willing to consent to participate in the study concerned with improving sexual activity after prostatectomy, the man has maintained normal sexual activity prior to prostatectomy\nPrior to prostatectomy PSA (prostate specific antigen) level<10 ng/mL\nAt the time of Prostatectomy, Pathological Gleason sum ≤7\nAt the time of Prostatectomy, Pathological stage ≤ T2c\n2 years or more postprostatectomy patients with PSA level ≤ 0.04 ng/mL without additional therapy after prostatectomy\nWho cannot satisfy sexual activity(more than 4 times) with proper sexual stimulation in spite of taking maximum dose of oral PDE5I(phos-phodiesterasetype-5 inhibitors) within last 8weeks.\nIIEF, EF(erectile function) domain score is under 17\nHave a consistent partner who is willing to engage in sexual activity more than twice per month during the study.\n\nDiabetes-associated Erectile Dysfunction\n\nHbA1c is between 6.5% and 10% of man over 20 years of age with diabetes\nWho cannot satisfy sexual activity(more than 4 times) with proper sexual stimulation in spite of taking maximum dose of oral PDE5I within last 8weeks.\nIIEF, EF domain score is under 17\nWho is willing to consent to participate in the study concerned with improving sexual activity\nHave a consistent partner who is willing to engage in sexual activity more than twice per month during the study.\n\nExclusion Criteria:\n\nHistory of bone marrow disorders\nSerum AST/ALT > 3 X upper limit of normal or Creatinine > 1.5 X upper limit of normal\nHistory of hypersensitivity against a gentamycin\nSevere cardiovascular disease(angina, arrhythmia, cardiac failure, stroke), kidney failure, respiratory failure\nPositive for human immunodeficiency virus (HIV), hepatitis B virus (HBV), hepatitis C virus (HCV) and syphilis test\nPositive for PSA or CEA or AFP (Carcinoembryonic antigen), history of cancer in the last five years (except Prostatic cancer) Uncontrolled hypertension or hypotension (systolic blood pressure > 170 or < 90 mm Hg, diastolic pressure > 100 or < 50 mm Hg)\nHbA1c exhibit greater than 10%\nMen on anticoagulant treatment\nHave a severe infectious disease\nTestosterone level is less than 200ng/dl\nHave a penile implant or willing to it\nPatients with morphological changes of the penis\nPatient's partner is trying to conceive during the trial period\nUnwilling to participate in the study\nParticipating in other clinical trials in the past 30 days\nUnable to compliance with protocol\nInappropriate patients to participate in the study according to the investigator",
      "HealthyVolunteers": "No",
      "Gender": "Male",
      "MinimumAge": "20 Years",
      "StdAgeList": {
        "StdAge": [
          "Adult",
          "Older Adult"
        ]
      }
    },
    "ContactsLocationsModule": {
      "OverallOfficialList": {
        "OverallOfficial": [
          {
            "OverallOfficialName": "Chungsu Kim, Ph.D",
            "OverallOfficialAffiliation": "AIDS Malignancy Consortium",
            "OverallOfficialRole": "Principal Investigator"
          }
        ]
      },
      "LocationList": {
        "Location": [
          {
            "LocationFacility": "Asan medical center",
            "LocationCity": "Seoul",
            "LocationCountry": "Korea, Republic of"
          }
        ]
      }
    },
    "ReferencesModule": {
      "ReferenceList": {
        "Reference": [
          {
            "ReferencePMID": "34326007",
            "ReferenceType": "derived",
            "ReferenceCitation": "You D, Jang MJ, Song G, Shin HC, Suh N, Kim YM, Ahn TY, Kim CS. Safety of autologous bone marrow-derived mesenchymal stem cells in erectile dysfunction: an open-label phase 1 clinical trial. Cytotherapy. 2021 Oct;23(10):931-938. doi: 10.1016/j.jcyt.2021.06.001. Epub 2021 Jul 27."
          }
        ]
      }
    }
  },
  "DerivedSection": {
    "MiscInfoModule": {
      "VersionHolder": "January 20, 2022"
    },
    "ConditionBrowseModule": {
      "ConditionMeshList": {
        "ConditionMesh": [
          {
            "ConditionMeshId": "D000007172",
            "ConditionMeshTerm": "Erectile Dysfunction"
          }
        ]
      },
      "ConditionAncestorList": {
        "ConditionAncestor": [
          {
            "ConditionAncestorId": "D000012735",
            "ConditionAncestorTerm": "Sexual Dysfunction, Physiological"
          },
          {
            "ConditionAncestorId": "D000020018",
            "ConditionAncestorTerm": "Sexual Dysfunctions, Psychological"
          },
          {
            "ConditionAncestorId": "D000001523",
            "ConditionAncestorTerm": "Mental Disorders"
          }
        ]
      },
      "ConditionBrowseLeafList": {
        "ConditionBrowseLeaf": [
          {
            "ConditionBrowseLeafId": "M9369",
            "ConditionBrowseLeafName": "Erectile Dysfunction",
            "ConditionBrowseLeafAsFound": "Erectile Dysfunction",
            "ConditionBrowseLeafRelevance": "high"
          },
          {
            "ConditionBrowseLeafId": "M14698",
            "ConditionBrowseLeafName": "Sexual Dysfunction, Physiological",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M21026",
            "ConditionBrowseLeafName": "Sexual Dysfunctions, Psychological",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M3967",
            "ConditionBrowseLeafName": "Mental Disorders",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M13625",
            "ConditionBrowseLeafName": "Psychotic Disorders",
            "ConditionBrowseLeafRelevance": "low"
          }
        ]
      },
      "ConditionBrowseBranchList": {
        "ConditionBrowseBranch": [
          {
            "ConditionBrowseBranchAbbrev": "BXS",
            "ConditionBrowseBranchName": "Urinary Tract, Sexual Organs, and Pregnancy Conditions"
          },
          {
            "ConditionBrowseBranchAbbrev": "BXM",
            "ConditionBrowseBranchName": "Behaviors and Mental Disorders"
          },
          {
            "ConditionBrowseBranchAbbrev": "All",
            "ConditionBrowseBranchName": "All Conditions"
          }
        ]
      }
    },
    "InterventionBrowseModule": {
      "InterventionBrowseLeafList": {
        "InterventionBrowseLeaf": [
          {
            "InterventionBrowseLeafId": "M28485",
            "InterventionBrowseLeafName": "Phosphodiesterase 5 Inhibitors",
            "InterventionBrowseLeafRelevance": "low"
          }
        ]
      },
      "InterventionBrowseBranchList": {
        "InterventionBrowseBranch": [
          {
            "InterventionBrowseBranchAbbrev": "All",
            "InterventionBrowseBranchName": "All Drugs and Chemicals"
          }
        ]
      }
    }
  }
}